Introducing the latest JUVÉDERM® innovation  >
EXPAND TO SEE ALL ALLERGAN BRANDS +
For Us Healthcare Professionals
Important Safety Information Patient Safety Information + Directions for use + FOR US PATIENTS Contact Us Set up Account
Product Information Training Practice resources Ordering Rewards Results

FOR US HEALTHCARE PROFESSIONALS

PRODUCT INFORMATION TRAINING PRACTICE RESOURCES ORDERING REWARDS RESULTS
Important Safety Information Patient Safety Information Directions for Use FOR US PATIENTS Contact Us Set Up Account
×
BOTOX® COSMETIC
(onabotulinumtoxinA)
KYBELLA®
(deoxycholic acid) injection 10 mg/ml
COOLSCULPTING®
LATISSE®
(bimatoprost ophthalmic solution) 0.03%
NATRELLE®
SKINMEDICA®
×
  • JUVÉDERM® ULTRA XC
  • JUVÉDERM® ULTRA PLUS XC
  • JUVÉDERM® ULTRA
  • JUVÉDERM® ULTRA PLUS
  • JUVÉDERM® VOLUMA® XC
  • JUVÉDERM® VOLBELLA® XC for Lip Augmentation
  • JUVÉDERM® VOLBELLA® XC for Undereye Hollows
  • JUVÉDERM® VOLLURE® XC
×
  • JUVÉDERM® ULTRA XC
  • JUVÉDERM® ULTRA PLUS XC
  • JUVÉDERM® ULTRA
  • JUVÉDERM® ULTRA PLUS
  • JUVÉDERM® VOLUMA® XC
  • JUVÉDERM® VOLBELLA® XC
  • JUVÉDERM® VOLLURE® XC
Read More +
JUVÉDERM® INJECTABLE GEL FILLERS INDICATIONS AND IMPORTANT SAFETY INFORMATION
The JUVÉDERM® Collection of Fillers includes JUVÉDERM VOLUMA™ XC, JUVÉDERM VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM VOLBELLA® XC. JUVÉDERM VOLUMA® XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. JUVÉDERM VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM VOLBELLA® XC is for injection into the lips for lip augmentation and for correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.
#1 selling filler in the US1,*
TAILORED TO ADD VOLUME, CREATING
LIFT and CONTOUR
in the Midface2
*Among individual dermal filler products.
Actual patient treated with JUVÉDERM VOLUMA®  XC. Results may vary.
#1 selling filler in the US1,*
TAILORED TO ADD VOLUME FOR
LIFT and CONTOUR
in the Midface2
JUVÉDERM VOLUMA® XC is the first and only FDA-approved filler to correct age-related volume loss in the midface for up to 2 years.2,†
ADD VOLUME FOR
LIFT IN THE MIDFACE2,3
  • • Smoother contour3
  • • Natural looking4
LASTS UP TO
2 YEARS2,†
†With optimal treatment.
SEE THE DIFFERENCE
Kathy
BEFORE
AFTER 1 MONTH
AT 2 YEARS
kathy-after kathy-before
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment, 1 month after treatment, and 2 years after treatment. A total of 3.5 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.2
Tami, 50s
BEFORE
AFTER 1 MONTH
tami-after tami-before
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 4.8 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.2
Nancy
BEFORE
AFTER 1 MONTH
nancy-before nancy-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.2
These photos are not of a clinical trial subject.
IMPROVED SATISFACTION    |    MORE YOUTHFUL APPEARANCE
In the clinical study, a majority of patients experienced
improvement in satisfaction over 2 years with optimal treatment.4,‡
6 months after treatment4

of patients were

MORE SATISFIED‡
(n = 205 )
2 years after treatment4

of patients were

MORE SATISFIED‡
(n = 157 )
‡Overall satisfaction score was obtained as an average score for responses on first 6 questions of Facial Appearance Evaluation. Improvement indicates an increase in the overall satisfaction score since baseline among treatment-group patients.4

In the clinical study, a majority of patients experienced
improvement in satisfaction over 2 years with optimal treatment.4,‡
6 months after treatmenT2,4
Patients said they looked
YOUNGER§
(n = 205 )
2 YEARS after treatmenT2,4
Patients said they looked
YOUNGER§
(n = 157 )
§Change in perceived age calculated by perceived age at follow-up visit less the perceived age at baseline as reported by treatment-group patients. A negative change indicated looking younger. A 10% reduction in age since baseline, based on self-perception, was considered clinically significant.4
watch injection training
The video reviews

  • • Midface facial anatomy
  • • Patient assessment
  • • Injection technique
TRAIN ONLINE NOW  >
Remember: Online injection training is required to purchase product.
<  LIPS AND perioral lines
lower face  >
To download before-and-after photos,
visit allergan brandbox  >
References: 1. Data on file, Allergan, 2015; Proforma Sales. 2. JUVÉDERM VOLUMA® XC Directions for Use, 2016. 3. JUVÉDERM VOLUMA® XC Patient Labeling, 2016. 4. Data on file, Allergan.
JUVÉDERM® INJECTABLE GEL FILLERS INDICATIONS AND IMPORTANT SAFETY INFORMATION
The JUVÉDERM® Collection of Fillers includes JUVÉDERM® VOLUMA® XC, JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM® VOLBELLA® XC. JUVÉDERM® VOLUMA® XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit and for augmentation of the chin region to improve the chin profile in adults over the age of 21. JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM® VOLBELLA® XC is for injection into the lips for lip augmentation and for correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.
JUVÉDERM® Collection of Fillers Important Information
INDICATIONS

JUVÉDERM® VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21.


JUVÉDERM® VOLLURE® XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.


JUVÉDERM® VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.


JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).


JUVÉDERM® Ultra XC injectable gel is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.
WARNINGS
•Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
•Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled
PRECAUTIONS
•To minimize the risks of potential complications, this product should only be used by healthcare professionals with appropriate experience and training on facial anatomy and product use in indicated area(s), vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications
•The potential risks of soft-tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
•The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each product have not been established in controlled clinical studies
•The safety for use of these products during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
•The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age for cheek augmentation and in patients between 22 and 80 years of age for chin augmentation
•The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and JUVÉDERM® VOLLURE® XC and JUVÉDERM® VOLBELLA® XC in patients under 22 years, has not been established
•As with all transcutaneous procedures, dermal filler implantation carries a risk of infection
•Dermal fillers should be used with caution in patients on immunosuppressive therapy
•Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
•Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
•If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site
•The safety for use of JUVÉDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established
•The safety of JUVÉDERM® VOLUMA® XC with cannula for cheek augmentation has not been established in patients with Fitzpatrick Skin Types V and VI
•JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
•The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
•Patients may experience late-onset adverse events with use of these dermal fillers, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC
•Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (130 lbs) body mass per year. The safety of injecting greater amounts has not been established







ADVERSE EVENTS
The most commonly reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. The majority were mild or moderate in severity. For JUVÉDERM® VOLUMA® XC, most resolved within 2 to 4 weeks. For JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, or JUVÉDERM® Ultra XC, most resolved within 14 days; and for JUVÉDERM® VOLBELLA® XC, most resolved within 30 days.
To report an adverse reaction with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1 877 345 5372. Please visit JuvedermDFU.com for more information.
Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-voluma-xc_dfu.pdf for JUVÉDERM® VOLUMA® XC
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-vollure-xc_dfu.pdf for JUVÉDERM® VOLLURE® XC
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-volbella_dfu.pdf for JUVÉDERM® VOLBELLA® XC
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf for JUVÉDERM® Ultra Plus XC
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-xc_dfu.pdf for JUVÉDERM® Ultra XC

Privacy Statement | California Privacy Policy | Terms of Use | Cookies Settings
JUVÉDERM®, VOLUMA®, VOLLURE®, VOLBELLA®, and their designs are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. © 2022 AbbVie. All rights reserved.
hcp.Juvederm.com JUV106549-v7 01/22 012613
×